The short answer
Avoid adding kava to phenobarbital without the prescriber’s review. Kava guidance advises against combining it with sedating substances, and phenobarbital can impair alertness.
What this answer covers
Oral Piper methysticum products; exact extract, dose and co-ingredients matter.
- Supplement or preparation
- Piper methysticum
- Medication ingredient
- phenobarbital
Why the combination needs review
NCCIH advises against combining kava with sedative substances. The concern here is additional impairment; a sleep or anxiety benefit in another setting would not establish safety of this combination.
What the clinical reports do not show
A controlled kava trial did not find benefit for its primary anxiety outcome. That trial was not a safety test with this medication. Reports of hospital phenobarbital treatment after stopping heavy kava are also different from taking both regularly.
Do not use spacing as a workaround
No validated time gap makes this combination safe. Bring the full kava label and describe regular or heavy use so the clinician can plan any changes rather than relying on a few hours between doses.
Watch for impaired alertness
Phenobarbital can cause drowsiness and impaired coordination. Avoid driving when affected, and seek urgent help for severe difficulty waking or breathing. Other sedating medicines and alcohol make a careful medication review especially important.
Evidence and practical considerations
Side effects & toxicity
Conditional avoidance/review is supported by botanical guidance and exact medication CNS effects; no protective spacing interval or exact combination risk rate.
- Exact scope
- Oral Piper methysticum products; exact extract, dose and co-ingredients matter. with Exact oral phenobarbital; parent and metabolites distinguished; no other drug/route assumed equivalent.
- Medication form and route
- oral supplement unless pregnancy section explicitly distinguishes neonatal injection
- Timing or duration
- Preparation, dose and duration determine applicability; chronic nutrition evidence is not a single-dose interaction.
What remains uncertain
- No controlled routine co-use safety trial. Withdrawal-treatment reports are a distinct clinical setting and do not establish supplement co-use safety.
Factors that may matter: exact supplement identity; dose; other medicines; clinical indication; baseline nutrition; pregnancy where relevant.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral phenobarbital.
Causes CNS depression and can impair driving; other CNS depressants can add to these effects. Adult plasma half-life is prolonged. Abrupt withdrawal after dependence can cause seizures and other serious symptoms. Long-term treatment warrants periodic clinical and laboratory assessment.
How this applies: Exact RxCUI 8134 IN and UNII YQE403BP4D, oral plain ingredient; no automatic sodium-injection or other barbiturate transfer.
Does not name the requested botanicals or establish supplement-specific interaction rates or spacing. Current DailyMed listing is unapproved drug other, not evidence of FDA approval.
Source 2: official guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the specified supplement.
Advises against use with sedative substances. Kava may cause dizziness and has been linked to rare severe liver injury, including with different extraction methods.
How this applies: Preparation-specific context; not a directly measured either requested antiseizure drug interaction.
Not a either requested antiseizure drug study. Intrinsic liver risk does not establish added either requested antiseizure drug hepatotoxicity; preparation and co-exposure vary.
Source 3: randomized placebo-controlled trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 adults randomized to three groups in an internet-based trial.
Neither active intervention improved its primary anxiety or insomnia outcome more than placebo.
How this applies: Preparation-specific context; not a directly measured either requested antiseizure drug interaction.
Not both active botanicals together, not either requested antiseizure drug co-use. Accessible abstract does not fully characterize dose and preparation; efficacy result is not proof of combination safety.
Source 4: original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: One hospitalized patient after escalating kava use and stopping.
Delirium resolved with supervised treatment.
How this applies: Apply only to the named drugs and study exposures; no unmeasured parent/metabolite or preparation equivalence.
Treatment after stopping heavy kava is not evidence that routine simultaneous kava and phenobarbital use is safe; other drugs and medical complications confound interpretation.
Source 5: original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: One patient who stopped a heavy-use kava/kratom beverage.
Symptoms improved during hospital care.
How this applies: Apply only to the named drugs and study exposures; no unmeasured parent/metabolite or preparation equivalence.
Mixed kava/kratom exposure, stopped before treatment; not a routine co-use safety study.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Exact current available claims reviewed against captured originals; no clinical review asserted. | |
| Research summary published |
Article revision: ad828b8f3650ac18
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.